Latest results FY2025 · Prices updated Oct 30, 2026
HQ: TokyoFounded 19255,026 employeesWebsite
A major Japanese pharmaceutical company. Strong in the field of oncology, focusing on research and development of innovative drugs. A member of the Roche Group.
Business segments (share of revenue)
Latest results
FY2025
vs. same period a year earlier
Company forecastFY2026
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| International Financial Services | 37% | ¥605.4B | ¥0 | 0.0% |
| Switzerland Business Segment | 35% | ¥573.1B | ¥0 | 0.0% |
| Japan Market | 29% | ¥472.4B | ¥0 | 0.0% |
Close (Oct 30, 2026)
¥6,822+0.1% (1Y)
Chugai +0.1% over 1Y, 13.0pt below the industry average (23 companies, +13.1%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2025FY | ¥1.3T | ¥598.8B | ¥434.0B | ¥2.5T | +7.5% |
| 2024FY | ¥1.2T | ¥542.0B | ¥387.3B | ¥2.2T | +5.3% |
| 2023FY | ¥1.1T | ¥439.2B | ¥325.5B | ¥1.9T | -11.8% |
| 2022FY | ¥1.3T | ¥533.3B | ¥374.4B | ¥1.9T | +26.0% |
| 2021FY | ¥999.8B | ¥421.9B | ¥303.0B | ¥1.5T | — |
Sources: annual securities reports, earnings releases and other public disclosures (Dec 2024)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
